Overall, the selective blockade of the CD28–B7 costimulatory pathway using CTLA4-Ig appears to be safe and well tolerated in MS patients and could be a promising strategy for controlling T-cell activity and inflammation in MS [77]. Here, CTLA4 is linked to myeloid sarcoma.